A Multiplex Test Assessing MiR663ame and VIMme in Urine Accurately Discriminates Bladder Cancer from Inflammatory Conditions
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Multiplex Test Assessing MiR663ame and VIMme in Urine Accurately Discriminates Bladder Cancer from Inflammatory Conditions
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 9, Issue 2, Pages 605
Publisher
MDPI AG
Online
2020-02-25
DOI
10.3390/jcm9020605
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- DNA-Methylation-Based Detection of Urological Cancer in Urine: Overview of Biomarkers and Considerations on Biomarker Design, Source of DNA, and Detection Technologies
- (2019) Louise Katrine Larsen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Identification of circulating miR-663a as a potential biomarker for diagnosing osteosarcoma
- (2019) Congwei Huang et al. PATHOLOGY RESEARCH AND PRACTICE
- European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update
- (2019) Marko Babjuk et al. EUROPEAN UROLOGY
- Novel urinary biomarkers for the detection of bladder cancer: A systematic review
- (2018) Wei Shen Tan et al. CANCER TREATMENT REVIEWS
- miR-663a inhibits tumor growth and invasion by regulating TGF-β1 in hepatocellular carcinoma
- (2018) Chengshuo Zhang et al. BMC CANCER
- Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends
- (2017) Sebastien Antoni et al. EUROPEAN UROLOGY
- Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
- (2017) J. Alfred Witjes et al. EUROPEAN UROLOGY
- Bladder cancer
- (2017) Oner Sanli et al. Nature Reviews Disease Primers
- miR-663a inhibits hepatocellular carcinoma cell proliferation and invasion by targeting HMGA2
- (2016) Weizhen Huang et al. BIOMEDICINE & PHARMACOTHERAPY
- Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer
- (2016) Jean-Pierre Roperch et al. BMC CANCER
- MicroRNA-663a is downregulated in non-small cell lung cancer and inhibits proliferation and invasion by targeting JunD
- (2016) Yi Zhang et al. BMC CANCER
- Economic Burden of Bladder Cancer Across the European Union
- (2016) Jose Leal et al. EUROPEAN UROLOGY
- A Prospective Blinded Evaluation of Urine-DNA Testing for Detection of Urothelial Bladder Carcinoma in Patients with Gross Hematuria
- (2016) Christina M. Dahmcke et al. EUROPEAN UROLOGY
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours
- (2016) Peter A. Humphrey et al. EUROPEAN UROLOGY
- miR-663 Suppresses Oncogenic Function of CXCR4 in Glioblastoma
- (2015) Y. Shi et al. CLINICAL CANCER RESEARCH
- MicroRNA-663 suppresses cell invasion and migration by targeting transforming growth factor beta 1 in papillary thyroid carcinoma
- (2015) Zhihong Wang et al. TUMOR BIOLOGY
- Diagnostic and prognostic epigenetic biomarkers in cancer
- (2015) Pedro Costa-Pinheiro et al. Epigenomics
- An epigenetic biomarker combination of PCDH17 and POU4F2 detects bladder cancer accurately by methylation analyses of urine sediment DNA in Han Chinese
- (2015) Yongqiang Wang et al. Oncotarget
- In Search of a Consensus: Evaluation of the Patient With Hematuria in an Era of Cost Containment
- (2014) Matthew T. Heller et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Diagnostic markers of urothelial cancer based on DNA methylation analysis
- (2013) Yoshitomo Chihara et al. BMC CANCER
- Hypermethylation of TWIST1 and NID2 in Tumor Tissues and Voided Urine in Urinary Bladder Cancer Patients
- (2013) Zeynep Yegin et al. DNA AND CELL BIOLOGY
- miR-663 Induces Castration-Resistant Prostate Cancer Transformation and Predicts Clinical Recurrence
- (2013) Li Jiao et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Epigenetic biomarkers in urological tumors: A systematic review
- (2011) Carmen Jerónimo et al. CANCER LETTERS
- Vimentin in cancer and its potential as a molecular target for cancer therapy
- (2011) Arun Satelli et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Three Epigenetic Biomarkers, GDF15, TMEFF2, and VIM, Accurately Predict Bladder Cancer from DNA-Based Analyses of Urine Samples
- (2010) V. L. Costa et al. CLINICAL CANCER RESEARCH
- Accuracy of Urine Cytology and the Significance of an Atypical Category
- (2009) Fadi Brimo et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Identification and Validation of the Methylated TWIST1 and NID2 Genes through Real-Time Methylation-Specific Polymerase Chain Reaction Assays for the Noninvasive Detection of Primary Bladder Cancer in Urine Samples
- (2009) Isabelle Renard et al. EUROPEAN UROLOGY
- Hypermethylated SFRP1, but none of other nine genes “informative” for western countries, is valuable for bladder cancer detection in mainland China
- (2009) Jinfeng Sun et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Bladder cancer
- (2009) Donald S Kaufman et al. LANCET
- The prognostic impact of NF-κB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer
- (2008) S Al-Saad et al. BRITISH JOURNAL OF CANCER
- Epigenetics in Cancer
- (2008) Manel Esteller NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started